GI Dynamics Selects Allenby Capital to Explore AIM Listing Option
May 02 2017 - 7:00PM
Business Wire
GI Dynamics®, Inc. (ASX:GID), a medical device company that has
commercialized EndoBarrier® in Europe, the Middle East and South
America for patients with type 2 diabetes and obesity, announces
Allenby Capital Limited’s engagement to explore options for seeking
admission of GI Dynamics shares to trade on the London Stock
Exchange’s AIM market.
Allenby Capital is a London-based NOMAD (nominated adviser) and
broker on the London Stock Exchange’s AIM market that focuses on
providing a range of advisory and transactional services to growing
businesses. Allenby Capital has played a leading role in numerous
successful listings and secondary fundraisings for its corporate
clients in various business sectors and geographical
jurisdictions.
“We look forward to working with Allenby Capital to explore
options for listing GI Dynamics shares on the AIM market,” said
Scott Schorer, GI Dynamics’ President and CEO. “Allenby Capital
comes highly recommended and has the relevant experience to fully
explore this opportunity. AIM represents an attractive public
equity market for international growth companies seeking to access
capital. We also view AIM as a method of increasing GI Dynamics
profile in our key European markets, which is synchronized with our
commercial focus.”
About GI Dynamics
GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier,
the first endoscopically-delivered device therapy approved for the
treatment of type 2 diabetes and obesity. EndoBarrier is approved
and commercially available in multiple countries outside the United
States. EndoBarrier is not approved for sale in the United
States and is limited by federal law to investigational use only in
the United States. Founded in 2003, GI Dynamics is headquartered in
Boston, Massachusetts. For more information, please
visit www.gidynamics.com.
Forward-Looking Statements
This announcement contains forward-looking statements concerning
our development and commercialization plans, potential revenues and
revenue growth, costs, excess inventory, profitability and
financial performance, ability to obtain reimbursement for our
products, clinical trials and associated regulatory submissions and
approvals, the number and location of commercial centers offering
the EndoBarrier, and our intellectual property position. These
forward-looking statements are based on GI Dynamics’ management’s
current estimates and expectations of future events as of the date
of this announcement. Furthermore, the estimates are subject to
several risks
and uncertainties that could cause actual results to differ
materially and adversely from those indicated in or implied by such
forward-looking statements. These risks and uncertainties include
but are not limited to, risks associated with the consequences of
terminating the ENDO trial and the possibility that future clinical
trials will not be successful or confirm earlier results. Further
risks are associated with obtaining funding from third parties; the
timing and costs of clinical trials; the timing of regulatory
submissions; and the timing, receipt and maintenance of regulatory
approvals. The timing and amount of other expenses and the timing
and extent of third-party reimbursement risks associated with
commercial product sales, including product performance,
competition, risks related to market acceptance of products,
intellectual-property risk; risks related to excess
inventory; and risks related to assumptions regarding the size
of the available market, the benefits of our products, product
pricing, timing of product launches, future financial results and
other factors, including those described in our filings with the
U.S. Securities and Exchange Commission. Given these uncertainties,
one should not place undue reliance on these forward-looking
statements. We do not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information or future events or otherwise, unless we are required
to do so by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170502006915/en/
GI DynamicsJanell Shields, +1 781-357-3246Investor Relations
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gi Dynamics (ASX:GID)
Historical Stock Chart
From Apr 2023 to Apr 2024